Clinical trials: CtDNA
Colorectal Cancer, Liver Metastases
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Conditions
- Colorectal Cancer, Liver Metastases, Stage IV Colorectal Cancer, Minimal Residual Disease
- Trial name
- NCT06287723
- Testing
- Blood sample/Liquid biopsy
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT05502523
- Testing
- Pulmonary Artery-First Surgical Technique, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Non Small Cell Lung Cancer
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
Lazertinib is an oral third-generation irreversible tyrosine kinase inhibitor (TKI) that has proved to selectively inhibit EGFR-TKI sensitizing mutations (exon 19 deletion or exon 21 L858R) and be effective in patients with…
- Trial name
- CHAMELEON (NCT06020989)
- Testing
- Lazertinib+Pemetrexed+Carboplatin, Lazertinib
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
Mutation, Neoplasms
Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
Pathway Genomics Corporation (Pathway Genomics), a San Diego, California company, is involved in the development and validation of new molecular diagnostic assays for the analysis of circulating tumor deoxyribonucleic acid (DNA)…
- Trial name
- H1000 (NCT02612350)
- Testing
- ctDNA Analysis for the Detection of Genetic Mutations
- Where
- United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Carcinoma, Renal Cell
KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers
Kidney cancer is a highly malignant disease with 950 new cases every year in Denmark. Diagnosis and treatment of kidney cancer patients presents many challenges because that early stages of the disease are often asymptomatic and…
- Trial name
- NCT04295174
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Odense University Hospital
Lymphomas
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
Lymphomas are the most common haemopathic malignancy. The 3 most common types are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) and follicular lymphoma (FL).
- Trial name
- BIOLYMPH2020 (NCT04417803)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pulmonary Nodules
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early.
- Trial name
- NCT03651986
- Testing
- ctDNA methylation analysis by NGS
- Where
- 23 sites in China
- Volunteers
- 10,560 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Metastatic Urothelial Carcinoma
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those…
- Trial name
- CARMA (NCT06050954)
- Testing
- Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer Stage III, Liver Metastasis Colon Cancer
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- NCT06111105
- Where
- 15 sites in Austria, Denmark and 3 more
- Volunteers
- 590 people
- Sponsor
- Claus Lindbjerg Andersen
Early Breast Cancer (EBC)
neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast Cancer
The goal of this observational study is to explore the utility of analytical techniques that enable the study of small amounts of tumor-derived material circulating in the blood, such as fragments of circulating tumor DNA (also…
- Trial name
- neoAGORA (NCT07718841)
- Testing
- biological samples, images, and clinical data
- Where
- 10 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Breast Cancer Research Group
Glioblastoma
Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in glioblastoma patients.
- Trial name
- NCT05541042
- Testing
- Observational only
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Provincial People's Hospital
Bladder Cancer
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.
- Trial name
- NCT07581496
- Where
- 2 sites in Switzerland
- Volunteers
- 35 people
- Sponsor
- University Hospital, Basel, Switzerland
Colorectal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care…
- Trial name
- NCT07023289
- Testing
- Telisotuzumab Adizutecan, Standard of Care
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 140 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment.
- Trial name
- ERIS (NCT06486142)
- Testing
- Afatinib/Dacomitinib, Osimertinib
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer.
- Trial name
- NCT07797218
- Testing
- Docetaxel, Pyrotinib, Trastuzumab (Herceptin)
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0…
- Trial name
- NCT05254782
- Where
- 3 sites in Canada
- Volunteers
- 360 people
- Sponsor
- University Health Network, Toronto
Stomach Neoplasms
Prediction of the Efficacy of ctDNA in Immunotherapy for Advanced Gastric Cancer
Gastric cancer is one of the common malignant tumors in China, with relatively high incident rate and mortality among the population.
- Trial name
- NCT04053725
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Anal Cancer
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
This phase 2 single-arm study will evaluate whether a shortened course of mildly hypofractionated radiation therapy given with standard concurrent chemotherapy (mitomycin C and capecitabine) can provide acceptable tumor control…
- Trial name
- SSIBLING (NCT07775209)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Neurofibromatosis Type 1
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant disorder, caused by heterozygous mutations of the NF1 tumor suppressor gene (chr.17q11.2).
- Trial name
- NCT01218152
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Circulating Tumor DNA (ctDNA), Gastric Cancer
Detection of Plasma Circulating Tumor DNA in Gastric Cancer
The aim of this study is to develop a protocol for detection of circulating tumor DNA (ctDNA) in plasma of patients with early stages of gastric cancer.
- Trial name
- NCT05027347
- Testing
- plasma circulating tumor DNA
- Where
- Vietnam
- Volunteers
- 200 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)